Drugs / MSP3-CRM-Vac4All
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05776017 | Mar → Dec 2023 | Plasmodium falciparum malaria | Vac4All | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSP3-CRM-Vac4All | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05776017 ↗ |
| Modality | Vaccine | “Malaria Vaccine Candidate MSP3-CRM-Vac4All/ Alhydrogel®” NCT05776017 ↗ |